GMAB:NSD-Genmab A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 46.38

Change

+0.11 (+0.24)%

Market Cap

USD 29.62B

Volume

0.46M

Avg Analyst Target

USD 40.00 (-13.76%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+32.54 (+8.42%)

USD155.19B 259.06 194.72
BNTX BioNTech SE

+62.63 (+17.80%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

-5.56 (-0.95%)

USD62.49B 16.70 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-0.46 (-0.23%)

USD51.84B 26.37 17.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

+1.64 (+0.48%)

USD31.54B N/A N/A
SGEN Seagen Inc

+5.02 (+3.17%)

USD28.78B 49.36 38.34
RPRX Royalty Pharma plc

-0.94 (-2.49%)

USD22.88B 31.06 13.91
ALNY Alnylam Pharmaceuticals, Inc

+4.63 (+2.59%)

USD21.02B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap
SCID Global X Scientific Beta .. 0.00 % 0.39 %

N/A

USD3.34M
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.55 %

+0.57 (+1.44%)

USD0.09B
FINT:CA First Trust International.. 0.00 % 0.33 %

N/A

USD9.17M
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.42 (+2.78%)

USD0.33B
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

+7.40 (+0.80%)

USD0.03B
EMID:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

N/A

USD8.09M
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.15 %

+0.04 (+0.51%)

USD0.09B
XEUM:LSE Xtrackers - MSCI Europe M.. 0.00 % 0.25 %

+47.80 (+0.40%)

USD0.05B
DX2I:F Xtrackers - MSCI Europe M.. 0.00 % 0.25 %

+0.68 (+0.49%)

USD0.05B
EL43:F Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

+0.05 (+0.33%)

USD0.29B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

+0.11 (+1.01%)

USD0.03B
DX2I:XETRA Xtrackers - MSCI Europe M.. 0.00 % 0.25 %

+0.80 (+0.58%)

USD0.05B
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.30 %

+0.07 (+0.49%)

USD0.29B
ETLI:XETRA Legal & General UCITS ETF.. 0.00 % 0.49 %

+0.11 (+1.01%)

USD0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.07% 76% C 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.07% 76% C 61% D-
Trailing 12 Months  
Capital Gain 28.23% 71% C- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.23% 71% C- 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.28% 65% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.28% 64% D 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 35.39% 79% C+ 51% F
Risk Adjusted Return 91.19% 97% A+ 91% A-
Market Capitalization 29.62B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.28 24% F 31% F
Price/Book Ratio 9.14 18% F 16% F
Price / Cash Flow Ratio 4.61 10% F 48% F
EV/EBITDA 3.77 41% F 87% B+
Management Effectiveness  
Return on Equity 32.38% 97% A+ 94% A
Return on Invested Capital 31.16% 93% A 94% A
Return on Assets 22.65% 99% A+ 99% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.33 63% D 54% F
Short Percent 0.25% 97% A+ 90% A-
Beta 0.59 84% B 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.